生物制剂治疗对银屑病相关心血管疾病的影响

doi:10.35541/cjd.20200649

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (2): 165-169.doi: 10.35541/cjd.20200649

生物制剂治疗对银屑病相关心血管疾病的影响

杨琦郑捷

上海交通大学医学院附属瑞金医院皮肤科 200025

收稿日期:2020-06-24 修回日期:2021-01-18 发布日期:2023-02-01
通讯作者: 郑捷 E-mail:jie-zheng2001@126.com
基金资助:
国家自然科学基金（81830095）

Effect of biologics on cardiovascular comorbidities of psoriasis

Yang Qi, Zheng Jie

Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2020-06-24 Revised:2021-01-18 Published:2023-02-01
Contact: Zheng Jie E-mail:jie-zheng2001@126.com
Supported by:
National Natural Science Foundation of China（81830095）

摘要/Abstract

摘要： 【摘要】银屑病易伴发心血管疾病，与动脉粥样硬化存在相似的致病机制，都涉及固有免疫的激活和自身反应性T细胞的活化。近年来，越来越多的生物制剂被运用于银屑病的系统治疗中，包括肿瘤坏死因子α、白细胞介素12/23和白细胞介素17A抑制剂，不同生物制剂的疗效、安全性及其对心血管疾病的影响也引起了皮肤科医生的重视。本文对银屑病和动脉粥样硬化共同的免疫机制，以及不同生物制剂对心血管疾病与相关代谢变化的影响进行了概述。

关键词: 银屑病, 心血管疾病, 动脉粥样硬化, 心血管事件, 生物制剂

Abstract: 【Abstract】 Psoriasis is prone to be accompanied by cardiovascular diseases. Psoriasis and atherosclerosis have similar pathogenesis, involving the activation of innate immunity and autoreactive T cells. In recent years, more and more biological agents have been applied to systemic treatment of psoriasis, including tumor necrosis factor-α, interleukin-12/23 inhibitors and interleukin-17A inhibitors. The efficacy and safety of different biological agents, as well as their impact on cardiovascular diseases, have also attracted the attention of dermatologists. This review summarizes the common immunological pathogenesis of psoriasis and atherosclerosis, as well as the effects of different biological agents on cardiovascular diseases and related metabolic changes.

Key words: Psoriasis, Cardiovascular diseases, Atherosclerosis, Cardiovascular events, Biological agents

杨琦郑捷. 生物制剂治疗对银屑病相关心血管疾病的影响[J]. 中华皮肤科杂志, 2023,56(2):165-169. doi:10.35541/cjd.20200649

Yang Qi, Zheng Jie. Effect of biologics on cardiovascular comorbidities of psoriasis[J]. Chinese Journal of Dermatology, 2023, 56(2): 165-169.doi:10.35541/cjd.20200649

参考文献 50

［1］	Dattilo G, Imbalzano E, Casale M, et al. Psoriasis and cardiovascular risk: correlation between psoriasis and cardiovascular functional indices［J］. Angiology, 2018,69（1）:31⁃37. doi: 10.1177/0003319717699329.
［2］	Fernández⁃Armenteros JM, Gómez⁃Arbonés X, Buti⁃Soler M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population⁃based study［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:128⁃135. doi: 10.1111/jdv.15159.
［3］	Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences［J］. Front Immunol, 2018,9:579. doi: 10.3389/fimmu.2018.00579.
［4］	Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows［J］. Front Immunol, 2018,9:1668. doi: 10.3389/fimmu.2018.01668.
［5］	Skov L, Thomsen SF, Kristensen LE, et al. Cause⁃specific mortality in patients with psoriasis and psoriatic arthritis［J］. Br J Dermatol, 2019,180（1）:100⁃107. doi: 10.1111/bjd.16919.
［6］	Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events［J］. J Am Acad Dermatol, 2017,77（4）:650⁃656.e3. doi: 10.1016/j.jaad.2017.06.028.
［7］	Ramezani M, Zavattaro E, Sadeghi M. Evaluation of serum lipid, lipoprotein, and apolipoprotein levels in psoriatic patients: a systematic review and meta⁃analysis of case⁃control studies［J］. Postepy Dermatol Alergol, 2019,36（6）:692⁃702. doi: 10.5114/ada.2019.91420.
［8］	Wan MT, Shin DB, Hubbard RA, et al. Psoriasis and the risk of diabetes: a prospective population⁃based cohort study［J］. J Am Acad Dermatol, 2018,78（2）:315⁃322. doi: 10.1016/j.jaad.2017. 10.050.
［9］	Kong Y, Zhang S, Wu R, et al. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis［J］. Lipids Health Dis, 2019,18（1）:171. doi: 10.1186/s12944⁃019⁃1115⁃3.
［10］	Baumer Y, Ng Q, Sanda GE, et al. Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis［J］. JCI Insight, 2018,3（1）:e97179. doi: 10.1172/jci.insight.97179.
［11］	Herbert D, Franz S, Popkova Y, et al. High⁃fat diet exacerbates early psoriatic skin inflammation independent of obesity: saturated fatty acids as key players［J］. J Invest Dermatol, 2018,138（9）:1999⁃2009. doi: 10.1016/j.jid.2018.03.1522.
［12］	Schön MP. Adaptive and innate immunity in psoriasis and other inflammatory disorders［J］. Front Immunol, 2019,10:1764. doi: 10.3389/fimmu.2019.01764.
［13］	Zhang Z, Meng P, Han Y, et al. Mitochondrial DNA⁃LL⁃37 complex promotes atherosclerosis by escaping from autophagic recognition［J］. Immunity, 2015,43（6）:1137⁃1147. doi: 10.1016/j.immuni.2015.10.018.
［14］	Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T⁃cell autoantigen in psoriasis［J］. Nat Commun, 2014,5:5621. doi: 10.1038/ncomms6621.
［15］	Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease［J］. Br J Dermatol, 2013,169（5）:1066⁃1070. doi: 10.1111/bjd.12525.
［16］	Lee S, Bartlett B, Dwivedi G. Adaptive immune responses in human atherosclerosis［J］. Int J MolSci, 2020,21（23）:9322. doi: 10.3390/ijms21239322.
［17］	Raggi P, Genest J, Giles JT, et al. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions［J］. Atherosclerosis, 2018,276:98⁃108. doi: 10.1016/j.atherosclerosis. 2018.07.014.
［18］	Ye J, Wang Y, Wang Z, et al. Roles and mechanisms of interleukin⁃12 family members in cardiovascular diseases: opportunities and challenges［J］. Front Pharmacol, 2020,11:129. doi: 10.3389/fphar.2020.00129.
［19］	Allam G, Abdel⁃Moneim A, Gaber AM. The pleiotropic role of interleukin⁃17 in atherosclerosis［J］. Biomed Pharmacother, 2018,106:1412⁃1418. doi: 10.1016/j.biopha.2018.07.110.
［20］	Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti⁃inflammatory drugs in patients with severe psoriasis: 5⁃year follow⁃up of a Danish nationwide cohort［J］. J Eur Acad Dermatol Venereol, 2015,29（6）:1128⁃1134. doi: 10. 1111/jdv.12768.
［21］	Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink［J］. J Invest Dermatol, 2015,135（9）:2189⁃2197. doi: 10.1038/jid.2015.87.
［22］	Wu JJ, Joshi AA, Reddy SP, et al. Anti⁃inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis［J］. J Eur Acad Dermatol Venereol, 2018,32（8）:1320⁃1326. doi: 10. 1111/jdv.14951.
［23］	Rungapiromnan W, Mason KJ, Lunt M, et al. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study［J］. J Eur Acad Dermatol Venereol, 2020,34（4）:769⁃778. doi: 10.1111/jdv.16018.
［24］	Champs B, Degboé Y, Barnetche T, et al. Short⁃term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta⁃analysis of randomised controlled trials［J］. RMD Open, 2019,5（1）:e000763. doi: 10.1136/rmdopen⁃ 2018⁃000763.
［25］	Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL⁃12/23 mAbbriakinumab in moderate⁃to⁃severe psoriasis［J］. J Invest Dermatol, 2012,132（2）:304⁃314. doi: 10.1038/jid.2011.304.
［26］	Lee MP, Desai RJ, Jin Y, et al. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis［J］. JAMA Dermatol, 2019,155（6）:700⁃707. doi: 10. 1001/jamadermatol.2019.0001.
［27］	Rungapiromnan W, Yiu Z, Warren RB, et al. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta⁃analysis of randomized controlled trials［J］. Br J Dermatol, 2017,176（4）:890⁃901. doi: 10.1111/bjd.14964.
［28］	Aksentijevich M, Lateef SS, Anzenberg P, et al. Chronic inflammation, cardiometabolic diseases and effects of treatment: psoriasis as a human model［J］. Trends Cardiovasc Med, 2020,30（8）:472⁃478. doi: 10.1016/j.tcm.2019.11.001.
［29］	Mehta NN, Shin DB, Joshi AA, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo⁃controlled trial［J］. Circ Cardiovasc Imaging, 2018,11（6）:e007394. doi: 10.1161/ CIRCIMAGING.117.007394.
［30］	Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double⁃blind, placebo⁃controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis （the VIP⁃U Trial）［J］. J Invest Dermatol, 2020,140（1）:85⁃93. doi: 10.1016/j.jid.2019.07.679.
［31］	Pirro M, Simental⁃Mendía LE, Bianconi V, et al. Effect of statin therapy on arterial wall inflammation based on 18F⁃FDG PET/CT: a systematic review and meta⁃analysis of interventional studies［J］. J Clin Med, 2019,8（1）:118. doi: 10.3390/jcm8010118.
［32］	Rivers JP, Powell⁃Wiley TM, Dey AK, et al. Visceral adiposity in psoriasis is associated with vascular inflammation by （18）F⁃Fluorodeoxyglucosepositron⁃emission tomography/computed tomography beyond cardiometabolic disease risk factors in an observational cohort study［J］. JACC Cardiovasc Imaging, 2018,11（2 Pt 2）:349⁃357. doi: 10.1016/j.jcmg.2017.08.014.
［33］	Kim BS, Lee WK, Pak K, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate⁃to⁃severe psoriasis: feasibility study using （18）F⁃fluorodeoxyglucose PET/CT［J］. J Am Acad Dermatol, 2019,80（5）:1322⁃1331. doi: 10.1016/j.jaad.2018.03. 011.
［34］	Gelfand JM, Shin DB, Duffin KC, et al. A Randomized placebo⁃controlled trial of secukinumab on aortic vascular inflammation in moderate⁃to⁃severe plaque psoriasis （VIP⁃S）［J］. J Invest Dermatol, 2020,140（9）:1784⁃1793. doi: 10.1016/j.jid.2020.01. 025.
［35］	Joshi AA, Lerman JB, Dey AK, et al. Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis［J］. JAMA Cardiol, 2018,3（10）:949⁃956. doi: 10. 1001/jamacardio.2018.2769.
［36］	Williams MC, Kwiecinski J, Doris M, et al. Low⁃attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT⁃HEART trial （Scottish computed tomography of the HEART）［J］. Circulation, 2020,141（18）:1452⁃1462. doi: 10.1161/CIRCULATIONAHA.119.044720.
［37］	Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study［J］. Cardiovasc Res, 2019,115（4）:721⁃728. doi: 10.1093/cvr/cvz009.
［38］	Oikonomou EK, Marwan M, Desai MY, et al. Non⁃invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk （the CRISP CT study）: a post⁃hoc analysis of prospective outcome data［J］. Lancet, 2018,392（10151）:929⁃939. doi: 10.1016/S0140⁃6736（18）31114⁃0.
［39］	Elnabawi YA, Oikonomou EK, Dey AK, et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index［J］. JAMA Cardiol, 2019,4（9）:885⁃891. doi: 10.1001/jamacardio. 2019.2589.
［40］	Osto E, Piaserico S, Maddalozzo A, et al. Impaired coronary flow reserve in young patients affected by severe psoriasis［J］. Atherosclerosis, 2012,221（1）:113⁃117. doi: 10.1016/j.atherosclerosis.2011.12.015.
［41］	Alba BK, Greaney JL, Ferguson SB, et al. Endothelial function is impaired in the cutaneous microcirculation of adults with psoriasis through reductions in nitric oxide⁃dependent vasodilation［J］. Am J Physiol Heart CircPhysiol, 2018,314（2）:H343⁃H349. doi: 10.1152/ajpheart.00446.2017.
［42］	Piaserico S, Osto E, Famoso G, et al. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis［J］. Atherosclerosis, 2016,251:25⁃30. doi: 10.1016/j.atherosclerosis.2016.05.036.
［43］	Choi H, Uceda DE, Dey AK, et al. Application of non⁃invasive imaging in inflammatory disease conditions to evaluate subclinical coronary artery disease［J］. Curr Rheumatol Rep, 2019,22（1）:1. doi: 10.1007/s11926⁃019⁃0875⁃0.
［44］	Von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks［J］. J Invest Dermatol, 2019,139（5）:1054⁃1062. doi: 10.1016/j.jid.2018.10. 042.
［45］	Groenendyk JW, Shukla P, Dey AK, et al. Association of aortic vascular uptake of （18）FDG by PET/CT and aortic wall thickness by MRI in psoriasis: a prospective observational study［J］. Eur J Nucl Med Mol Imaging, 2019,46（12）:2488⁃2495. doi: 10.1007/s00259⁃019⁃04454⁃w.
［46］	Vlachopoulos C, Gravos A, Georgiopoulos G, et al. The effect of TNF⁃a antagonists on aortic stiffness and wave reflections: a meta⁃analysis［J］. Clin Rheumatol, 2018,37（2）:515⁃526. doi: 10.1007/s10067⁃017⁃3657⁃y.
［47］	Eder L, Joshi AA, Dey AK, et al. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease［J］. Arthritis Rheumatol, 2018,70（3）:408⁃416. doi: 10.1002/art.40366.
［48］	Hjuler KF, Bøttcher M, Vestergaard C, et al. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis［J］. JAMA Dermatol, 2016,152（10）:1114⁃1121. doi: 10.1001/jamadermatol.2016.1984.
［49］	Toussirot E. The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition［J］. Metabolites, 2020,10（3）. doi: 10.3390/metabo10030107.
［50］	Takamura S, Takahashi A, Inoue Y, et al. Effects of tumor necrosis factor⁃α, interleukin⁃23 and interleukin⁃17A inhibitors on bodyweight and body mass index in patients with psoriasis［J］. J Dermatol, 2018,45（9）:1130⁃1134. doi: 10.1111/1346⁃8138.14526.

[1]	何谐栗玉珍. 靶向JAK-STAT信号通路治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(3): 273-278.
[2]	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识[J]. 中华皮肤科杂志, 2023, 56(3): 191-203.
[3]	周健俞晨王刚. 司库奇尤单抗治疗13例难治性局限性脓疱型银屑病的临床疗效与安全性观察[J]. 中华皮肤科杂志, 2023, 56(3): 247-251.
[4]	胡琨杨晶王巧林陈军臣张谧朱武张斌窦冠珅 Wendong Chen, 匡叶红. [开放获取] 依奇珠单抗治疗银屑病短期疗效的单中心病例回顾性研究[J]. 中华皮肤科杂志, 2023, 56(3): 210-215.
[5]	罗帅寒天龙海陆前进. 2022年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2023, 56(3): 266-269.
[6]	阮诗钒张鹏林婷婷罗仁炜鲍思怡薛晨瑶童泽群张亮亮龚婷纪超. 寻常型银屑病与血脂异常的相关性研究[J]. 中华皮肤科杂志, 2023, 0(3): 20220322-e20220322.
[7]	苑辰闫言王宝玺. 反常性痤疮的生物治疗进展[J]. 中华皮肤科杂志, 2023, 56(3): 270-273.
[8]	王召阳向欣陈云刘苗朝阳赵欣荣张振华刘元香马琳徐子刚. 生物制剂与甲氨蝶呤治疗儿童重度斑块状银屑病疗效及安全性比较[J]. 中华皮肤科杂志, 2023, 56(2): 112-117.
[9]	贾元源毛秋雨杨婧怡闵玮. 度普利尤单抗治疗中重度老年特应性皮炎临床疗效观察[J]. 中华皮肤科杂志, 2023, 56(2): 125-129.
[10]	田晶梁源马琳. 度普利尤单抗治疗儿童特应性皮炎的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210730-e20210730.
[11]	陈良宏孙艳王敬玉吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210875-e20210875.
[12]	黄贺张学军. 白细胞介素23抑制剂古塞奇尤单抗在银屑病治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(2): 181-184.
[13]	杨莹郭青侯素春闵雪田佳彬乔朱卉林佳琳王小飞乌兰图雅张振颖李正风王彬刘晓明. 【开放获取】接受生物制剂治疗的银屑病患者COVID-19疫苗接种情况及对原发病影响的单中心横断面研究[J]. 中华皮肤科杂志, 2023, 56(1): 59-63.
[14]	郑佳媛余炳前陈显侠骆志成. 成人寻常型银屑病瘙痒特征及对生活质量的影响调查[J]. 中华皮肤科杂志, 2022, 55(9): 790-794.
[15]	肖春英王刚. 朗格汉斯细胞在银屑病中的作用研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 830-834.

生物制剂治疗对银屑病相关心血管疾病的影响

Effect of biologics on cardiovascular comorbidities of psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 50

相关文章 15

Metrics

本文评价

推荐阅读 10